[Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Cinacalcet is a new drug with antiparathyroid effects that belongs to the class of calcimimetics. It increases the sensitivity of the calcium-sensing receptor (CaSR) to calcium, thus inducing a decrease in plasma parathyroid (PTH) levels. In patients with uncontrolled secondary hyperparathyroidism due to uremia, cinacalcet has been shown to decrease the levels of PTH even in those optimally treated with calcium and 1-ahydroxylated vitamin D. Cinacalcet decreases plasma calcium and plasma PTH levels in patients with primary hyperparathyroidism or parathyroid cancer.
Vestergaard
Peter
P
Osteoporoseklinikken, Arhus Universitetshospital, Arhus Sygehus, Medicinsk Endokrinologisk Afdeling C, Arhus C. p-vest@post4.tele.dk
Nielsen
Lars Rejnmark
LR
Mosekilde
Leif
L
D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000188:drug therapy*; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D009281:Naphthalenes / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D010282:Parathyroid Neoplasms / Q000188:drug therapy*; D044169:Receptors, Calcium-Sensing / Q000187:drug effects; D014511:Uremia / Q000188:drug therapy*
D009281:Naphthalenes; D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D002118:Calcium; D000069449:Cinacalcet